Greenville, North Carolina, United States of America
  •  6
    Combination Treatment with Apricoxib and IL-27 Enhances Inhibition of Epithelial-Mesenchymal Transition in Human Lung Cancer Cells through a STAT1 Dominant Pathway (review)
    with P. Kachroo, P. C. Pagano, J. Yanagawa, G. Wang, T. C. Walser, K. Krysan, S. Sharma, John M. S., S. M. Dubinett, and J. M. Lee
    The cyclooxygenase 2 pathway has been implicated in the molecular pathogenesis of many malignancies, including lung cancer. Apricoxib, a selective COX-2 inhibitor, has been described to inhibit epithelial-mesenchymal transition in human malignancies. The mechanism by which apricoxib may alter the tumor microenvironment by affecting EMT through other important signaling pathways is poorly defined. IL-27 has been shown to have anti-tumor activity and our recent study showed that IL-27 inhibited EM…Read more